Israel - English - Ministry of Health

unipharm trading ltd, israel - metformin hydrochloride; sitagliptin as hydrochloride - film coated tablets - metformin hydrochloride 1000 mg; sitagliptin as hydrochloride 50 mg - metformin and sitagliptin - sitar plus is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use: sitar plus should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. sitar plus has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitar plus.

Israel - English - Ministry of Health

unipharm trading ltd, israel - metformin hydrochloride; sitagliptin as hydrochloride - film coated tablets - metformin hydrochloride 850 mg; sitagliptin as hydrochloride 50 mg - metformin and sitagliptin - sitar plus is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use: sitar plus should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. sitar plus has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitar plus.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 113.38 mg (equivalent: sitagliptin, qty mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin sandoz pharma is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: ? monotherapy when metformin is considered inappropriate due to intolerance; or ? in combination with other anti-hyperglycaemic agents, including insulin. [see sections 5.1 pharmacodynamic properties ? clinical trials and 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitagliptin sandoz pharma is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: ? monotherapy when metformin is considered inappropriate due to intolerance; or ? in combination with other anti-hyperglycaemic agents, including insulin. [see sections 5.1 pharmacodynamic properties ? clinical trials and 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 28.34 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin sandoz pharma is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: ? monotherapy when metformin is considered inappropriate due to intolerance; or ? in combination with other anti-hyperglycaemic agents, including insulin. [see sections 5.1 pharmacodynamic properties ? clinical trials and 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 1000mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 100mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 100mg; metformin hydrochloride 1000mg

Canada - English - Health Canada

sivem pharmaceuticals ulc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet - 50mg; 850mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 850mg

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as phosphate salt - tablets extended release - sitagliptin as phosphate salt 100 mg; metformin hydrochloride 1000 mg - metformin - januet xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is appropriate